Diasorin

Name: Diasorin
Address: Strada Crescentino snc, Saluggia, 13040, IT
Telephone: +390161487093
Price range: Not Applicable

Chiama Indicazioni Sito Web

Global leader in the laboratory diagnostics market. Starting from 2021, the company also commercializes Life Science products.

DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics. The Group was founded in 1968 and is headquartered in Saluggia (Italy). Its line of products used by diagnostic laboratories that are part of hospital facilities or operate independently can meet the needs of the following clinical areas: infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology. DiaSorin can offer the market an assay menu that is unique for its width and presence of specialty tests, which identify us as “the” in vitro diagnostics specialist. DiaSorin also provides Life Science products that have a wide range of applications including academic and scientific research, public health and food safety, plant pathogens detection and cell counts, viability, and cell health analyses.

08/10/2026

That's a wrap on .

Every demo at the booth sent $10 to Reach Out and Read, and we hit our $1,000 goal, helping get books in kids' hands at their checkups.

We also sponsored the AAP Friends of Children Fund 5K and ran alongside conference attendees to show our support.

Thanks to every pediatrician who stopped by to talk strep, RSV, and congenital CMV testing. See you in Chicago next October!

04/10/2026

Back at Booth 2731 this morning for day two of in San Diego. Yesterday, almost every pediatrician who stopped by asked some version of the same question: can I get a result while the family's still in the room?

We're showing two tools built for pediatric care: LIAISON NES® for fast molecular answers on strep A, flu, COVID-19, and RSV, and Simplexa® cCMV Direct for congenital CMV testing in newborns.

We're also raising money for Out and Read, which helps pediatricians hand families a book at well-child visits. Every product demo means a $10 donation from us, and our goal is $1,000 by Monday.

Stop by, say hi to Sanchez, Libudziewski, Petrisko, Jones, and Magstadt, and help us fill the thermometer.
https://hubs.ly/Q04z6dq-0

02/10/2026

New peer-reviewed findings in Microbiology Spectrum highlight how the Simplexa® C. auris Direct assay is helping laboratories address one of today’s most urgent infection-prevention challenges.

As a De Novo IVD assay for Candida auris colonization detection, Simplexa® C. auris Direct provides a standardized solution for detecting patients suspected of C. auris colonization, helping healthcare facilities act quickly to prevent transmission and protect vulnerable patients.

Key results:
• 100% sensitivity vs. culture followed by MALDI-TOF identification
• 95% overall diagnostic accuracy
• Strong agreement with culture and PCR LDTs
• No cross-reactivity with other fungi or bacteria
• No environmental contamination detected during testing

The assay showed strong agreement with LDTs and a streamlined workflow on the LIAISON® MDX platform—enabling faster screening to support confident infection‑control decisions and safer patient care.

Explore the full publication: https://hubs.li/Q04z557d0

30/09/2026

➤ 1 in 200 newborns is diagnosed with congenital CMV every year.
➤ 21 days is the window of time after birth that a newborn should be tested for congenital CMV.
➤ 60 minutes is how quickly Simplexa® Congenital CMV Direct can provide diagnostic results for saliva swab and/or urine samples.

When a newborn may have congenital CMV, timely and accurate detection can make all the difference. To provide the best quality diagnostics for your newborn patients, implement the Simplexa® Congenital CMV Direct assay: the only FDA-cleared PCR assay for the detection of CMV in saliva swabs and urine in neonates.

Discover more

Attending ? Stop by Booth #2731 to learn more about the Simplexa® Congenital CMV Direct assay: https://hubs.li/Q04yQK2g0

28/09/2026

Stop by Booth #2731 to explore the LIAISON NES®, connect with our team, and learn more about our work in diagnostic solutions. We look forward to engaging with healthcare professionals and industry peers throughout the event.

Register today: https://hubs.li/Q04y6Qx40

23/09/2026

We look forward to connecting with attendees at in San Diego, October 2-6.

Visit us at Booth #2731 to learn more about the LIAISON NES® and meet members of our team. We welcome the opportunity to discuss how diagnostic innovation helps support advances in healthcare and laboratory testing.

Register for AAP 2026: https://hubs.li/Q04y6HJL0

14/09/2026

Early planning can make a significant difference when responding to Candida auris.

In this upcoming Labroots webinar, Dr. Preeti Pancholi will discuss the growing impact of C. auris, the importance of timely laboratory identification, and strategies that can help strengthen surveillance and infection prevention efforts.

Don't miss key insights that could help improve your healthcare facility’s preparedness for C. auris.

Reserve your spot today: https://hubs.li/Q04xjWWx0

11/09/2026

As recent Cyclospora outbreaks have demonstrated, identifying the true cause of diarrheal illness can be challenging when symptoms overlap across multiple infectious agents.

The LIAISON PLEX® GI Flex Assay helps laboratories quickly rule in or rule out a broad range of pathogens, supporting timely patient management and infection control decisions.

Key benefits include:
• Detection of bacterial, viral, and parasitic targets in a single assay
• Inclusion of Cyclospora cayetanensis detection
• Detection of 8 parasites among 24 total targets

Flexible menu. Comprehensive answers. Intentional diagnostics.

Learn more: https://hubs.li/Q04xcvHz0

09/09/2026

There is no one-size-fits-all approach to gastrointestinal testing. Seasonal outbreaks, patient history, and clinical presentation can all influence which pathogens should be considered during the diagnostic process.

In our latest blog, Dr. Michelle Tabb discusses how the current Cyclospora outbreak underscores the importance of flexible testing strategies and highlights broader trends shaping the future of GI diagnostics.

Read the blog to learn more: https://hubs.li/Q04vNm_c0

07/09/2026

Join Preeti Pancholi, PhD, D(ABMM), Co-Director of Clinical Microbiology and Director of Molecular Microbiology at The Ohio State University, for a Labroots-hosted webinar exploring the evolving role of clinical microbiology in addressing Candida auris.

Gain insights into the pathogen's changing epidemiology, current diagnostic approaches, including MALDI-TOF and molecular methods, and the growing challenge of antifungal resistance.

Learn how rapid identification and collaboration between clinical microbiology and infection prevention teams can support effective patient care, surveillance, and infection control strategies.

Register here: https://hubs.li/Q04wPWvh0

Indirizzo

Strada Crescentino Snc
Saluggia
13040

Telefono

+390161487093

Sito Web

http://www.diasorin.com/

Notifiche

Lascia la tua email e sarai tra i primi a sapere quando Diasorin pubblica novità e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Vuoi che la tua azienda sia in cima alla categoria azienda a Saluggia?